<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200919048753N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-11-20</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>effectiveness of added cognitive task training to multi directional treadmill training in patients with Parkinson's disease</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the added value of cognitive task training on a multi directional treadmill training program on gait parameters in patients with Parkinson’s disease: An Assessor Blind Randomized Controlled Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-12-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>32</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51272</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: All participants are entered to study by neurologists. According to related past studies the sample size estimated 28 subjects (14 subjects per groups) and with considering the 20% attrition with ratio of 1:1 (treadmill group:treadmill+cognitive exercise group) for each of group at least 16 subjects were considered. Assignment of people to groups will be based on the Block Balanced Randomization (BBR) method. After two months from the end of the study, follow up will be performed in both study groups, Randomization description: Assignment of patients in two groups of treadmill and treadmill + cognitive exercise was done by Block Balanced Randomization (BBR) method. The Randomization Sequence is generated with using the free web site at http://www.randomization.com. Non-transparent and sealed envelopes will be used to conceal the assignment of individuals to groups, Blinding description: The assessor will not be aware of which intervention will be administered to which subject. The data analyzer also does not know the groups (treadmill or treadmill+cognitive exercise).</study_design>
      <phase>2</phase>
      <hc_freetext>Parkinson's disease.</hc_freetext>
      <i_freetext>Intervention 1: control group :  The people in the control group will be treated with treadmill exercise for 6 weeks. they will walk on treadmill in all four directions. Exercises in the control group will be offered 3 times a week, each training session lasts about 30 minutes(5min warm-up,[7min forward,7min backward,3min right sideway,3min left sideway],5min cooldown).All training sessions will be performed under the supervision of a physiotherapist. Intervention 2: Intervention group : The people in the intervention group will be treated with treadmill exercise+cognitive exercises for 6 weeks. They will walk on treadmill in all four directions. Exercises in the intervention group will be offered 3 times a week, each training session lasts about 30 minutes(5min warm-up,20min exercising[7min forward,7min backward,3min right sideway,3min left sideway],5min cooldown). Cognitive exercising will be counting backwards from 100 by subtracting 3’s, Naming words starting with a special letter such as M. All training sessions will be performed under the supervision of a physiotherapist.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Fallahzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Chamran Blvd . abiverdi1 school of rehabilitation sciences</address>
        <city>shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7194733669</zip>
        <telephone>+98 71 3626 1081</telephone>
        <email>ffallahzadeh@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohsen Razeghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Chamran Blvd Abiverdi 1 school of rehabilitation sciences</address>
        <city>shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7194733669</zip>
        <telephone>+98 71 3626 1081</telephone>
        <email>razeghm@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>patients with idiopathic Parkinson's disease according to United Kingdom(UK)Bank
patients in Hoehn and Yahr scale (H&amp;Y I-III)  stages of Parkinson's disease
patients should be MED on state
patients should be able to independent walking at least for 6 min based on Unified Parkinson's Disease Rating Scale (UPDRS)
Montreal Cognitive Assessment (MOCA)≤24 for cognitive system</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>other neurological disorders such as CVA, Alzheimer, severe neuropathic impairments
A history of any serious orthopedic problems such as surgery or fractures that prevent you from walking on the treadmill
Existence of any severe respiratory and pulmonary diseases that prevent the intervention protocol
Having a history of heart failure or coronary heart disease and stroke that prevents the intervention protocol
Existence of hearing and vision impairment that prevents the correct performance of tests
History of head and neck surgery
History of Deep Brain Stimulation
History of malignant diseases that prevent the intervention protocol
Musculoskeletal pain that prevents the intervention protocol
Participate in exercise programs such as treadmills for at least the past two months</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G20</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Parkinson's disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>control group :  The people in the control group will be treated with treadmill exercise for 6 weeks. they will walk on treadmill in all four directions. Exercises in the control group will be offered 3 times a week, each training session lasts about 30 minutes(5min warm-up,[7min forward,7min backward,3min right sideway,3min left sideway],5min cooldown).All training sessions will be performed under the supervision of a physiotherapist.</i_keyword>
      <i_keyword>Intervention group : The people in the intervention group will be treated with treadmill exercise+cognitive exercises for 6 weeks. They will walk on treadmill in all four directions. Exercises in the intervention group will be offered 3 times a week, each training session lasts about 30 minutes(5min warm-up,20min exercising[7min forward,7min backward,3min right sideway,3min left sideway],5min cooldown). Cognitive exercising will be counting backwards from 100 by subtracting 3’s, Naming words starting with a special letter such as M. All training sessions will be performed under the supervision of a physiotherapist.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Walking speed. Timepoint: before intervention, immediately  after 6 weeks of intervention, after 2 moths from the end of intervention. Method of measurement: 6 min walking test.</prim_outcome>
      <prim_outcome>Stride length. Timepoint: before intervention, immediately after 6 weeks of intervention, after 2 moths from the end of intervention. Method of measurement: meters.</prim_outcome>
      <prim_outcome>Motor system function. Timepoint: before intervention, immediately after 6 weeks of intervention, after 2 moths from the end of intervention. Method of measurement: Unified Parkinson's Disease rating Scale(UPDRS III).</prim_outcome>
      <prim_outcome>Cognitive function. Timepoint: before intervention, immediately after 6 weeks of intervention, after 2 moths from the end of intervention•. Method of measurement: MOCA test.</prim_outcome>
      <prim_outcome>The percentage difference between stride length and walking speed. Timepoint: before intervention, immediately after 6 weeks of intervention, after 2 moths from the end of intervention•. Method of measurement: Dual task cost methods(DTcost).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of life. Timepoint: before intervention, immediately after 6 weeks of intervention, after 2 moths from the end of intervention•. Method of measurement: PDQ39 questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-08-19</approval_date>
        <contact_name>Ethics committee of research in Shiraz University of Medical Science</contact_name>
        <contact_address>Central building of Shiraz University of Medical Science, Zand Ave shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
